Oxford Financial Group LTD. LLC Has $1.40 Million Position in Johnson & Johnson (NYSE:JNJ)

Oxford Financial Group LTD. LLC lowered its holdings in Johnson & Johnson (NYSE:JNJ) by 14.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 9,674 shares of the company’s stock after selling 1,669 shares during the quarter. Oxford Financial Group LTD. LLC’s holdings in Johnson & Johnson were worth $1,399,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in JNJ. Swedbank AB increased its holdings in shares of Johnson & Johnson by 5.3% in the third quarter. Swedbank AB now owns 2,215,108 shares of the company’s stock worth $358,980,000 after acquiring an additional 111,570 shares in the last quarter. Principal Financial Group Inc. increased its holdings in shares of Johnson & Johnson by 10.5% in the third quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company’s stock worth $562,723,000 after acquiring an additional 329,473 shares in the last quarter. United Bank grew its holdings in shares of Johnson & Johnson by 5.6% during the third quarter. United Bank now owns 3,788 shares of the company’s stock worth $614,000 after buying an additional 202 shares in the last quarter. Segall Bryant & Hamill LLC bought a new position in shares of Johnson & Johnson during the third quarter worth about $5,883,000. Finally, Cornerstone Advisors LLC grew its holdings in shares of Johnson & Johnson by 4.7% during the third quarter. Cornerstone Advisors LLC now owns 120,102 shares of the company’s stock worth $19,464,000 after buying an additional 5,400 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In other news, VP Robert J. Decker sold 6,999 shares of the company’s stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares in the company, valued at $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research analysts recently issued reports on JNJ shares. Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a report on Wednesday, February 19th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Barclays increased their price target on Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research report on Tuesday, January 28th. Wells Fargo & Company cut their price objective on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Finally, Citigroup cut their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $171.33.

Johnson & Johnson Stock Performance

JNJ stock opened at $162.93 on Friday. The business has a 50 day moving average of $156.57 and a 200-day moving average of $156.34. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The firm has a market cap of $392.63 billion, a PE ratio of 24.50, a P/E/G ratio of 2.56 and a beta of 0.47. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. During the same quarter in the prior year, the firm earned $2.29 EPS. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. As a group, sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.04%. The ex-dividend date of this dividend was Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.